Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1499-1507 , December 2007

Comparable Outcomes after Nonmyeloablative Hematopoietic Cell Transplantation with Unrelated and Related Donors

  • Marco Mielcarek

      Affiliations

    • Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Medicine, University of Washington School of Medicine, Seattle, Washington
    • Corresponding Author InformationCorrespondence and reprint requests: Marco Mielcarek, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, PO Box 19024, Seattle, WA 98109-1024. Tel: 206-667-2827; Fax: 206-667-6124.
    • ,
  • Barry E. Storer

      Affiliations

    • Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Biostatistics, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Brenda M. Sandmaier

      Affiliations

    • Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Medicine, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Mohamed L. Sorror

      Affiliations

    • Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • David G. Maloney

      Affiliations

    • Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Medicine, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Effie Petersdorf

      Affiliations

    • Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Medicine, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Paul J. Martin

      Affiliations

    • Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Medicine, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Rainer Storb

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, Washington

Received 6 July 2007 ,Accepted 2 September 2007.

References 

  1. Hurley CK, Fernandez VM, Setterholm M. Maximizing optimal hematopoietic stem cell donor selection from registries of unrelated adult volunteers. Tissue Antigens. 2003;61:415–424
  2. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–771
  3. Beatty PG, Hansen JA, Anasetti C, et al. Marrow transplantation from unrelated HLA-matched volunteer donors. Transplant Proc. 1989;21:2993–2994
  4. Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell–depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990;322:485–494
  5. Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med. 1993;119:207–214
  6. Schiller G, Feig SA, Territo M, et al. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol. 1994;88:72–78
  7. Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood. 1995;86:1228–1234
  8. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515–3520
  9. Petersdorf EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood. 1997;89:1818–1823
  10. Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, and DR identical unrelated donor marrow transplantation. Blood. 1995;86:1606–1613
  11. Speiser DE, Tiercy JM, Rufer N, et al. High-resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood. 1996;87:4455–4462
  12. Horowitz MM, Loberiza FR, Bredeson CN, et al. Transplant registries: guiding clinical decisions and improving outcomes. Oncology. 2001;15:649–659
  13. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400
  14. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  15. Sandmaier BM, Maloney DG, Gooley T, et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen. Blood. 2001;98(Part 1):742a–743a
  16. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595–3599
  17. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637
  18. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood. 2004;104:961–968
  19. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078
  20. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204–3213
  21. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754–2759
  22. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882–1891
  23. Nestel FP, Price KS, Seemayer TA, et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med. 1992;175:405–413
  24. Xun CQ, Thompson JS, Jennings CD, et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H2-incompatible transplanted SCID mice. Blood. 1994;83:2360–2367
  25. Colson YL, Lange J, Fowler K, et al. Mechanism for cotolerance in nonlethally conditioned mixed chimeras: negative selection of the Vβ T-cell receptor repertoire by both host and donor bone marrow–derived cells. Blood. 1996;88:4601–4610
  26. Manilay JO, Pearson DA, Sergio JJ, et al. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation. 1998;66:96–102
  27. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–2030
  28. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234–3241
  29. Mielcarek M, Burroughs L, Leisenring W, et al. Prognostic relevance of “early-onset” graft-versus-host disease following nonmyeloablative hematopoietic cell transplantation. Br J Haematol. 2005;129:381–391
  30. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756–762
  31. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004;10:178–185
  32. Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant. 2006;12:454–465
  33. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA- matched related donors. Blood. 2004;104:1550–1558
  34. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919
  35. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007;11:2744–2748
  36. Prentice RL, Kalbfleisch JD, Peterson AV, et al. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541–554
  37. Makuch RW. Adjusted survival curve estimation using covariates. J Chronic Dis. 1982;35:437–443
  38. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971–1977
  39. Parimon T, Au DH, Martin PJ, et al. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med. 2006;144:407–414
  40. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104:2976–2980
  41. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767–1777
  42. Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007;13:601–607
  43. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962–968
  44. Ottinger HD, Ferencik S, Beelen DW, et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood. 2003;102:1131–1137
  45. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695–5702
  46. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816–2825

PII: S1083-8791(07)00441-7

doi: 10.1016/j.bbmt.2007.09.004

Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1499-1507 , December 2007

Article Tools

* Image Usage & Resolution